Autoimmune Diseases

CD19 CAR T-cell Therapy Without Lymphodepletion Shows Promise in Pemphigus Vulgaris: Insights from the RESET-PV Trial

By MedXY 08/02/2026

Early results from the RESET-PV trial indicate that CD19 CAR T-cell therapy without lymphodepleting preconditioning is feasible and safe for pemphigus vulgaris, offering significant clinical improvement and durable B-cell depletion.

news Ophthalmology Rheumatology

Ocular Inflammation Linked to Higher Risk of Anti-Adalimumab Antibodies in Autoimmune Disease Patients

By MedXY 05/29/2026

Ocular inflammation was linked to a higher risk of anti-adalimumab antibody formation in patients treated with adalimumab. More than 20% developed antibodies, supporting closer monitoring and therapeutic drug testing in high-risk patients.

Cardiology Clinical Updates news Specialties

Evolocumab for Intensive LDL Cholesterol Reduction in Autoimmune and Inflammatory Disease Patients: Insights from the FOURIER Trial

By MedXY 08/17/2025

Evolocumab significantly lowers LDL cholesterol and substantially reduces cardiovascular events in patients with autoimmune/inflammatory diseases alongside statin therapy, according to the FOURIER trial analysis.